EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische Studie

Dual Antiplatelet Therapy After Embolic Stroke of Undetermined Source: A Subgroup Analysis of the CHANCE-2 Trial

Xuewei Xie iD, Jing Jing iD, Xia Meng, S Claiborne Johnston iD, Philip M Bath iD, Zixiao Li iD, Xingquan Zhao iD, Yilong Wang iD, Qin Xu iD, Anxin Wang iD, Yong Jiang iD, Hao Li und 2 weitere

Stroke · 2024-07 · 55 (7) · 1739-1747

DOI: 10.1161/strokeaha.124.046834 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Stroke, 2024-07. Verfasst von Xuewei Xie und 13 weiteren Autor:innen. Beteiligte Einrichtung: China National Clinical Research Center for Neurological Diseases, Beijing (X.X., J.J., X.M., Z.L., X.Z., Yilong Wang, Q.X., A.W., Y.J., H.L., Yongju…. Hauptthemen laut MEDLINE: Platelet Aggregation Inhibitors, Clopidogrel, Aspirin, Ticagrelor. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The atherosclerotic sources of embolism are a significant contributor to embolic stroke of undetermined source (ESUS). However, there is limited evidence for the efficacy of intensive dual antiplatelet therapy for ESUS. We conducted an investigation to determine whether gene-directed dual antiplatelet therapy could reduce the risk of recurrent stroke in patients with ESUS. METHODS: CHANCE-2 (Clopidogrel in High-Risk Patients with Acute Nondisabling Cerebrovascular Events-II) was an investigator-initiated, multicenter, randomized, double-blind, placebo-controlled trial that objectively compared ticagrelor plus aspirin and clopidogrel plus aspirin in patients with minor stroke or transient ischemic attack who carried CYP2C19 loss-of-function alleles in China. All study participants were classified into ESUS and non-ESUS groups for the prespecified exploratory analysis. Cox proportional hazards models were used to assess the interaction of the state of ESUS with the effects of dual antiplatelet therapy with ticagrelor-aspirin versus clopidogrel-aspirin, adjusting for sociodemographic and clinical factors. RESULTS: The subgroup analysis comprised 5796 participants (90.4% of the total 6412 participants) in the CHANCE-2 trial, with a median age of 64.9 years (range, 57.0–71.4 years), of whom 1964 (33.9%) were female. These participants underwent diffusion-weighted imaging as part of the study protocol. After systematic evaluation, 15.2% of patients (881/5796) were deemed to have ESUS. The incidence of stroke recurrence in patients with ESUS was found to be 5.6% in the ticagrelor-aspirin group and 9.2% in the clopidogrel-aspirin group (hazard ratio, 0.57 [95% CI, 0.33–0.99]; P =0.04). In patients without ESUS, the respective incidence rates were 5.6% and 7.5% (hazard ratio, 0.72 [95% CI, 0.58–0.90]; P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Platelet Aggregation InhibitorsClopidogrelAspirinTicagrelorDual Anti-Platelet TherapyEmbolic StrokeHumansMiddle AgedFemaleMaleAgedDouble-Blind MethodCytochrome P-450 CYP2C19Stroke

Stichwörter der Autor:innen

aspirinembolic strokeplatelet aggregation inhibitorsstroketicagrelor

Substanzen

Platelet Aggregation InhibitorsClopidogrelAspirinTicagrelorCytochrome P-450 CYP2C19CYP2C19 protein, human

Autor:innen und Institutionen

  • China National Clinical Research Center for Neurological Diseases, Beijing (X.X., J.J., X.M., Z.L., X.Z., Yilong Wang, Q.X., A.W., Y.J., H.L., Yongjun Wang).
  • Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China (X.X., J.J., X.M., Z.L., X.Z., Yilong Wang, Q.X., A.W., Y.J., H.L., Yongjun Wang).
  • Tiantan Neuroimaging Center of Excellence, Beijing, China (J.J.).
  • Department of Neurology, University of California, San Francisco (S.C.J.).
  • Stroke Trials Unit, Mental Health and Clinical Neuroscience, University of Nottingham, United Kingdom (P.M.B.).

ORCID-Profile: Xuewei Xie, Jing Jing, S Claiborne Johnston, Philip M Bath, Zixiao Li, Xingquan Zhao, Yilong Wang, Qin Xu, Anxin Wang, Yong Jiang, Yongjun Wang

Zitieren

APA

Xie, X., Jing, J., Meng, X., Johnston, S. C., Bath, P. M., Li, Z., Zhao, X., Wang, Y., Xu, Q., Wang, A., Jiang, Y., Li, H., Wang, Y., & CHANCE-2 Investigators (2024). Dual Antiplatelet Therapy After Embolic Stroke of Undetermined Source: A Subgroup Analysis of the CHANCE-2 Trial. Stroke, 55(7), 1739-1747. https://doi.org/10.1161/strokeaha.124.046834

Vancouver

Xie X, Jing J, Meng X, Johnston SC, Bath PM, Li Z, et al. Dual Antiplatelet Therapy After Embolic Stroke of Undetermined Source: A Subgroup Analysis of the CHANCE-2 Trial. Stroke. 2024;55(7):1739-1747. doi:10.1161/strokeaha.124.046834

BibTeX
@article{Xie2024,
  author = {Xie, Xuewei and Jing, Jing and Meng, Xia and Johnston, S Claiborne and Bath, Philip M and Li, Zixiao and Zhao, Xingquan and Wang, Yilong and Xu, Qin and Wang, Anxin and Jiang, Yong and Li, Hao and Wang, Yongjun and CHANCE-2 Investigators, CHANCE-2 Investigators},
  title = {Dual Antiplatelet Therapy After Embolic Stroke of Undetermined Source: A Subgroup Analysis of the CHANCE-2 Trial},
  journal = {Stroke},
  year = {2024},
  volume = {55},
  number = {7},
  pages = {1739--1747},
  doi = {10.1161/strokeaha.124.046834}
}
Kostenlos starten →